Drugs / MCMV3068A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01753167 | Dec 2012 → Oct 2014 | cytomegalovirus infection | Genentech, Inc. | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MCMV3068A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01753167 ↗ |
| Modality | Monoclonal antibody | “RG7667, a novel combination of two anticytomegalovirus (anti-CMV) monoclonal IgG1 antibodies (MCMV5322A and MCMV3068A)” PMID 29133549 ↗ Jan 2018 |